A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2016
At a glance
- Drugs Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Sponsors AbbVie
- 20 Apr 2016 Results assessing potential clinical biomarkers that correlated with venetoclax sensitivity presented at the 107th Annual Meeting of the American Association for Cancer Research.
- 17 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 09 Dec 2014 Interim results in 32 patients presented at the 56th Annual Meeting and Exposition of the American Society of Hematology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History